EP0064484A2 - Method for fluorescence spectroscopic determination of a biologically active substance - Google Patents

Method for fluorescence spectroscopic determination of a biologically active substance Download PDF

Info

Publication number
EP0064484A2
EP0064484A2 EP82850077A EP82850077A EP0064484A2 EP 0064484 A2 EP0064484 A2 EP 0064484A2 EP 82850077 A EP82850077 A EP 82850077A EP 82850077 A EP82850077 A EP 82850077A EP 0064484 A2 EP0064484 A2 EP 0064484A2
Authority
EP
European Patent Office
Prior art keywords
fluorescence
lantanide
chelate
split
marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP82850077A
Other languages
German (de)
French (fr)
Other versions
EP0064484A3 (en
EP0064484B1 (en
Inventor
Ilkka Hemmilä
Salifu Dakubu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wallac Oy
Original Assignee
Wallac Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wallac Oy filed Critical Wallac Oy
Priority to AT82850077T priority Critical patent/ATE21173T1/en
Publication of EP0064484A2 publication Critical patent/EP0064484A2/en
Publication of EP0064484A3 publication Critical patent/EP0064484A3/en
Application granted granted Critical
Publication of EP0064484B1 publication Critical patent/EP0064484B1/en
Expired legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/40—Rare earth chelates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/80—Fluorescent dyes, e.g. rhodamine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/805—Optical property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample

Definitions

  • the present invention refers to a method for fluorescence spectroscopic determination of a biological substance provided with a marker consisting of a lantanide chelate complex formed by a lantanide coupled to the substance via a chelate forming compound, such as an EDTA-analogue.
  • an antibody or an antigen or its conjugate is usually provided with an easily detectable marker which at present usually consists of a radioactive isotope.
  • an easily detectable marker which at present usually consists of a radioactive isotope.
  • the disadvantage of using radioactive isotopes is their limited storage time and the fact that one wishes to decrease the use of radioactive substances within medicine for health and environment reasons.
  • An alternative to the radioimmunological methods are the fluoroimmunological methods where the marker is a fluorescent substance.
  • a special problem in fluorescence determinations within the immunological field is that serum has a relatively strong fluorescence which gives rise to high background levels for most fluorescence markers.
  • This fluorescence of serum derives mainly from different proteins which however have relatively short excitation- and emission wavelengths (excitation maximum at 280 nm, emission maximum at 340 nm) and thus, it does not constitute a significant source of noise.
  • Serum does however also give rise to other types of fluorescence, presumably deriving from other compounds than protein, this fluorescence appearing at longer wavelengths (excitation at 340 nm, emission at 460-470 nm) and thus gives rise to roice phenomena which are more difficult to deal with.
  • the background is also affected by the scattering of the sample.
  • the scattering gives rise to an interference, especially if markers with a small Stoke's shift (less than 50 nm) are used. Because of the high background fluorescence and the scattering of the fluorescence the sensitivity of markers is decreased by 50-100 times if used in serum as compared to their use in pure buffer.
  • the attached compounds have a strong inherent fluorescence and the surface made from glass or plastic is often also fluorescent and additionally has disturbing light scattering properties.
  • the fluorescence measuring from a surface is thus more difficult from a measuring point of view than the measurement of a solution.
  • a marker which is used in an immunological system has to have as high as fluorescence as possible, a relatively long emission wavelength (more than 500 nm), a high Stoke's shift and the property of being coupled (covalently to the antibody or the antigen) without a negative effect on the conjugation properties.
  • a fluorescent marker meeting these requirements is described in the Swedish Patent Application 7902078-8 and is formed by a lantanide chelate made up from a lantanide and an aromatic S-diketone, which is coupled to the compound via an EDTA-analogue so as to obtain a fluorescent lantanide complex.
  • This marker furthermore has the essential property of a long fluorescent time, 50 - 1000 psec which makes it possible to use an instrumentation technique described for instance in the U.S. patent 4,058,732 in accordance with which the sample is excited by a laser pulse of a short duration, the fluorescence being detected only when the fluorescence from the noise sources has declined.
  • the disadvantage of using the above described marker is that the B-diketones disturb the immunoreaction and when they are supplied after the termination of the immunoreaction a very long time is required for the formation of the ternary chelate and furthermore, the protein used is often coupled to a surface, for instance the wall of a test tube which makes measurements of a sufficient accuracy difficult to carry out.
  • a lantanide for instance europium
  • a suitable deterqent such as Triton-X100
  • Triton-X100 a suitable deterqent
  • the following table gives examples of some of the ⁇ -diketones well suited for this purpose:
  • a synergistic compound such as a so-called Lewis base should be added.
  • a group of such bases consist of N-heterocyclic compounds, such as o-phenanthroline and another group consists of phosphines and phosphine oxides, e.g. trioctylphosphineoxide (TOPO).
  • TOPO trioctylphosphineoxide
  • the measuring could take place for instance in a system consisting of a buffer with pH 2.8 - 3.5 (for instance phthalate-HCL) containing 2-NTA 10 - 100 pM, TOPO 10 - 100 ⁇ M and Triton X100 0.1 - 0.5 %.
  • a buffer with pH 2.8 - 3.5 for instance phthalate-HCL
  • 2-NTA 10 - 100 pM TOPO 10 - 100 ⁇ M
  • Triton X100 0.1 - 0.5 %.
  • FIG. 1 shows the fluorescence in such a system (curve marked by circles) developed as the function of time as compared to the system where the lantanide is coupled to the protein (curve marked by squares).
  • the method according to the invention has been tested by using Europium in a model in which the Europium was coupled to I gG of sheep-anti-rabbit IgG and the same protein as an antibody in a solid phase with rabbit IgG as antigen. Both methods give roughly the same standard curve.
  • the essential advantage of the method according to the invention is that the measuring can take place at an earlier time (after about 30 minutes of incubation as compared to 8-10 hours) and with a higher accuracy and a higher fluorescent intensity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

In a method for fluorescence spectroscopic determination of a biological substance provided with a marker consisting of a lantanide chelate complex formed by a lantanide coupled to the substance via a chelate forming compound, such as an EDTA-analogue, the lantanide ion or the complete chelate before the detection is split from the active substance for instance by adding a buffer with a pH-value below 3.5 and a splitting detergent, whereafter the excitation in the determination takes place in the solution by using a short radiation pulse and the fluorescence from the marker is detected when the fluorescence from the noise sources has substantially ceased.

Description

  • The present invention refers to a method for fluorescence spectroscopic determination of a biological substance provided with a marker consisting of a lantanide chelate complex formed by a lantanide coupled to the substance via a chelate forming compound, such as an EDTA-analogue.
  • In quantitative immunological determinations an antibody or an antigen or its conjugate is usually provided with an easily detectable marker which at present usually consists of a radioactive isotope. The disadvantage of using radioactive isotopes is their limited storage time and the fact that one wishes to decrease the use of radioactive substances within medicine for health and environment reasons. An alternative to the radioimmunological methods are the fluoroimmunological methods where the marker is a fluorescent substance.
  • A special problem in fluorescence determinations within the immunological field is that serum has a relatively strong fluorescence which gives rise to high background levels for most fluorescence markers. This fluorescence of serum derives mainly from different proteins which however have relatively short excitation- and emission wavelengths (excitation maximum at 280 nm, emission maximum at 340 nm) and thus, it does not constitute a significant source of noise. Serum does however also give rise to other types of fluorescence, presumably deriving from other compounds than protein, this fluorescence appearing at longer wavelengths (excitation at 340 nm, emission at 460-470 nm) and thus gives rise to roice phenomena which are more difficult to deal with. In addition to the inherent fluorescence of serum the background is also affected by the scattering of the sample. The scattering gives rise to an interference, especially if markers with a small Stoke's shift (less than 50 nm) are used. Because of the high background fluorescence and the scattering of the fluorescence the sensitivity of markers is decreased by 50-100 times if used in serum as compared to their use in pure buffer.
  • Another problem arises in the fluorescence determination where the antibodies and the biologically active compound which is subject to the analysis are attached to a surface such as the wall of a test tube in addition to their internal coupling. Thus, the attached compounds have a strong inherent fluorescence and the surface made from glass or plastic is often also fluorescent and additionally has disturbing light scattering properties. The fluorescence measuring from a surface is thus more difficult from a measuring point of view than the measurement of a solution.
  • The requirements of a marker which is used in an immunological system are that it has to have as high as fluorescence as possible, a relatively long emission wavelength (more than 500 nm), a high Stoke's shift and the property of being coupled (covalently to the antibody or the antigen) without a negative effect on the conjugation properties.
  • A fluorescent marker meeting these requirements is described in the Swedish Patent Application 7902078-8 and is formed by a lantanide chelate made up from a lantanide and an aromatic S-diketone, which is coupled to the compound via an EDTA-analogue so as to obtain a fluorescent lantanide complex. This marker furthermore has the essential property of a long fluorescent time, 50 - 1000 psec which makes it possible to use an instrumentation technique described for instance in the U.S. patent 4,058,732 in accordance with which the sample is excited by a laser pulse of a short duration, the fluorescence being detected only when the fluorescence from the noise sources has declined.
  • The disadvantage of using the above described marker is that the B-diketones disturb the immunoreaction and when they are supplied after the termination of the immunoreaction a very long time is required for the formation of the ternary chelate and furthermore, the protein used is often coupled to a surface, for instance the wall of a test tube which makes measurements of a sufficient accuracy difficult to carry out.
  • It is an object of the present invention to provide a method in which these disadvantages are eliminated and according to which the measuring can be carried out after a very short time with a high accuracy. The characteristics of the invention will appear from the claims attached to the specification.
  • According to the invention a lantanide, for instance europium, is separated from EDTA by using a suitable deterqent, such as Triton-X100, at a low pH-value, suitably below 3.5. According to the invention it is furthermore desirable to amplify the fluorescence after the separation by adding β-diketones. The following table gives examples of some of the β-diketones well suited for this purpose:
    Figure imgb0001
  • In order to further improve the fluorescence, especially in water solutions, since water has a strong inhibitant effect, some synergistic compound such as a so-called Lewis base should be added. A group of such bases consist of N-heterocyclic compounds, such as o-phenanthroline and another group consists of phosphines and phosphine oxides, e.g. trioctylphosphineoxide (TOPO). The properties of these compounds and the way in which they affect the fluorescence are described for instance in the following publications: Halverson 1964 J.Chem.Phys. 41, 157; Kareseva & Karesev, 1975 Koord. Khim. 1, 926; Muraveva 1977, Zh. Neorg. Khim. 22, 3009; Makarchuk 1979 Ukr. Khim. Zh. 45, 656; Taketatsu 1979, Anal. Chim. Acta 108, 429 and Brittain 1980, Inorg. Chem. 19, 640.
  • According to the invention the measuring could take place for instance in a system consisting of a buffer with pH 2.8 - 3.5 (for instance phthalate-HCL) containing 2-NTA 10 - 100 pM, TOPO 10 - 100 µM and Triton X100 0.1 - 0.5 %.
  • The diagram in Fig. 1 shows the fluorescence in such a system (curve marked by circles) developed as the function of time as compared to the system where the lantanide is coupled to the protein (curve marked by squares).
  • The method according to the invention has been tested by using Europium in a model in which the Europium was coupled to IgG of sheep-anti-rabbit IgG and the same protein as an antibody in a solid phase with rabbit IgG as antigen. Both methods give roughly the same standard curve. The essential advantage of the method according to the invention is that the measuring can take place at an earlier time (after about 30 minutes of incubation as compared to 8-10 hours) and with a higher accuracy and a higher fluorescent intensity.

Claims (6)

1. Method for fluorescence spectroscopic determination of a biological substance provided with a marker consisting of a lantanide chelate complex formed of a lantanide coupled to the substance via a chelate forming compound, such as an EDTA-analogue, characterized in that the lantanide ion or the complete chelate before the detection is split from the active substance, whereafter the excitation in the determination takes place in the solution by using a short radiation pulse and the fluorescence from the marker is detected when the fluorescence from the noise sources has substantially ceased.
2. Method according to claim 1, characterized in that the split takes place by adding a buffer with a pH-value below 3.5 and a splitting detergent.
3. Method according to claim 2, characterized in that the detergent is Triton X100.
4. Method according to claim 1, characterized in that after the split further s-diketone is added.
5. Method according to claim 1, characterized in that after the split a Lewis base is added.
6. Method according to claim 5, characterized in that the base is trioctylphosphineoxide (TOPO).
EP82850077A 1981-04-30 1982-04-08 Method for fluorescence spectroscopic determination of a biologically active substance Expired EP0064484B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT82850077T ATE21173T1 (en) 1981-04-30 1982-04-08 METHOD FOR FLUORESCENCE-SPECTROSCOPIC DETERMINATION OF BIOLOGICALLY ACTIVE SUBSTANCES.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8102753A SE425439B (en) 1981-04-30 1981-04-30 IMMUNOLOGICAL ANALYSIS WITH LANTANIDE CHELAT COMPLEX AS MARKOR
SE8102753 1981-04-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP85200392.0 Division-Into 1985-03-15

Publications (3)

Publication Number Publication Date
EP0064484A2 true EP0064484A2 (en) 1982-11-10
EP0064484A3 EP0064484A3 (en) 1983-01-19
EP0064484B1 EP0064484B1 (en) 1986-07-30

Family

ID=20343715

Family Applications (2)

Application Number Title Priority Date Filing Date
EP85200392A Ceased EP0159066A1 (en) 1981-04-30 1982-04-08 Method for separating the lanthanide marker form a lanthanide marked immunochemical component
EP82850077A Expired EP0064484B1 (en) 1981-04-30 1982-04-08 Method for fluorescence spectroscopic determination of a biologically active substance

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP85200392A Ceased EP0159066A1 (en) 1981-04-30 1982-04-08 Method for separating the lanthanide marker form a lanthanide marked immunochemical component

Country Status (6)

Country Link
US (1) US4565790A (en)
EP (2) EP0159066A1 (en)
JP (1) JPS57186170A (en)
AT (1) ATE21173T1 (en)
DE (1) DE3272260D1 (en)
SE (1) SE425439B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381567B2 (en) 2002-03-08 2008-06-03 Wallac Oy Dissociative fluorescence enhancement assay
US7691647B2 (en) 2005-01-21 2010-04-06 Siemens Healthcare Diagnostics Inc. Compositions for use as a signal generation component and methods of using same
WO2017127684A1 (en) 2016-01-21 2017-07-27 SeLux Diagnostics, Inc. Methods for rapid antimicrobial susceptibility testing
US9834808B2 (en) 2016-01-21 2017-12-05 SeLux Diagnostics, Inc. Methods for rapid antibiotic susceptibility testing
WO2018119439A1 (en) 2016-12-23 2018-06-28 SeLux Diagnostics, Inc. Methods for improved rapid antimicrobial susceptibility testing
US11845976B2 (en) 2019-08-27 2023-12-19 SeLux Diagnostics, Inc. Systems and methods for performing antimicrobial susceptibility testing

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301395L (en) * 1983-03-15 1984-09-16 Wallac Oy KELATIZING COMPOUNDS WITH FUNCTIONAL GROUPS WHICH ALLOW COVALENT COUPLING TO BIO-ORGANIC MOLECULES
US4629693A (en) * 1984-03-27 1986-12-16 Syntex (U.S.A.) Inc. Sensitivity in fluorescence assays in icteric samples
US5830769A (en) * 1985-03-18 1998-11-03 Wieder; Irwin Homogeneous fluorassay methods employing fluorescent background rejection and water-soluble rare earth metal chelates
US4761481A (en) * 1985-03-18 1988-08-02 Baxter Travenol Laboratories, Inc. Substituted pyridine derivatives
SE8502573D0 (en) * 1985-05-23 1985-05-23 Jouko Kanakre FLUORESCENT LANTHANIDE CHELATES USEFUL AS LABELS OF PHYSIOLOGICALLY ACTIVE MATERIALS
IT1186733B (en) * 1985-06-05 1987-12-16 Eniricerche Spa TRIPEPTIDIC COMPOUNDS WITH HYPOTHENSIVE ACTION
US5155216A (en) * 1985-08-15 1992-10-13 Amoco Corporation Nucleic acids labeled with a chemiluminescent acridine ester
WO1987002708A1 (en) * 1985-10-24 1987-05-07 Siska Diagnostics, Inc. Lanthanide chelate-tagged nucleic acid probes
US5585279A (en) * 1986-01-23 1996-12-17 Davidson; Robert S. Time-resolved luminescence binding assays using a fluorescent transition metal label other than ruthenium
GB8601646D0 (en) * 1986-01-23 1986-02-26 Davidson R S Binding assay & reagent
US4727024A (en) * 1986-05-12 1988-02-23 Martin Koocher Binding assays involving formation and detection of light scattering crystals
EP0272320B1 (en) 1986-06-17 1994-03-23 Baxter Diagnostics Inc. Homogeneous fluoroassay methods employing fluorescent background rejection
US4925804A (en) * 1986-06-17 1990-05-15 Baxter International Inc. Interligand metal transfer assay
GB8622855D0 (en) * 1986-09-23 1986-10-29 Ekins R P Determining biological substance
SE8703682L (en) * 1987-09-24 1989-03-25 Wallac Oy HOMOGENIC DETERMINATION METHOD USING AFFINITY REACTIONS
US4978625A (en) * 1987-10-19 1990-12-18 Becton, Dickinson And Company Fluorescence immunoassay using water insoluble dyes
WO1989004375A1 (en) * 1987-10-23 1989-05-18 Siska Diagnostics, Inc. Lanthanide chelate-tagged nucleic acid probes
EP0493745A1 (en) * 1990-12-21 1992-07-08 Dojindo Laboratories Fluorescent compound, complex, reagent, and specific binding assay employing said reagent
FI88545C (en) * 1991-03-12 1993-05-25 Jouko Kankare Bestaemningsmetod
US5792330A (en) * 1995-05-31 1998-08-11 Board Of Regents, The University Of Texas System Lanthanide metal cations for concurrent detection and separation in capillary electrophoresis
US7745142B2 (en) * 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US7070921B2 (en) 2000-04-28 2006-07-04 Molecular Devices Corporation Molecular modification assays
US7632651B2 (en) * 1997-09-15 2009-12-15 Mds Analytical Technologies (Us) Inc. Molecular modification assays
US20050227294A1 (en) * 1997-09-15 2005-10-13 Molecular Devices Corporation Molecular modification assays involving lipids
US6030840A (en) * 1998-06-15 2000-02-29 Nen Life Sciences, Inc. Neutral enhancement of lanthanides for time resolved fluorescence
US6838292B1 (en) 1999-04-19 2005-01-04 Alion Science And Technology Corporation Detection of biological warfare agents
US6653146B1 (en) 1999-11-15 2003-11-25 Chemclean Corporation Bio-burden visualization system
JP4545337B2 (en) * 2001-03-23 2010-09-15 オリンパス株式会社 microscope
WO2003003063A2 (en) * 2001-06-28 2003-01-09 Ia, Inc. Fiber-optic sensor array
EP1437338B1 (en) * 2001-10-10 2009-09-16 Hitachi High-Technologies Corporation Luminous compounds and labeling reagents using the same
CA2581639C (en) * 2004-09-30 2016-07-26 Molecular Devices Corporation Luminescent lanthanide complexes
US7482444B2 (en) * 2006-03-13 2009-01-27 Wallac Oy Terminating substrates for DNA polymerases
US8778614B2 (en) 2010-08-24 2014-07-15 Enzo Life Sciences, Inc. Assays for detecting modified compounds
CN103969432B (en) * 2014-03-27 2016-02-17 中国科学院福建物质结构研究所 A kind of rare earth nano material dissolves Enhanced time resolved fluorometric immune analysis method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058732A (en) * 1975-06-30 1977-11-15 Analytical Radiation Corporation Method and apparatus for improved analytical fluorescent spectroscopy
FR2353854A1 (en) * 1976-05-31 1977-12-30 Technion Res & Dev Foundation SPECIFIC LINK ANALYSIS METHOD AND REAGENT
US4259313A (en) * 1978-10-18 1981-03-31 Eastman Kodak Company Fluorescent labels

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341957A (en) * 1975-11-26 1982-07-27 Analytical Radiation Corporation Fluorescent antibody composition for immunofluorometric assay
US4283382A (en) * 1977-12-28 1981-08-11 Eastman Kodak Company Fluorescent labels comprising rare earth chelates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058732A (en) * 1975-06-30 1977-11-15 Analytical Radiation Corporation Method and apparatus for improved analytical fluorescent spectroscopy
FR2353854A1 (en) * 1976-05-31 1977-12-30 Technion Res & Dev Foundation SPECIFIC LINK ANALYSIS METHOD AND REAGENT
US4259313A (en) * 1978-10-18 1981-03-31 Eastman Kodak Company Fluorescent labels

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381567B2 (en) 2002-03-08 2008-06-03 Wallac Oy Dissociative fluorescence enhancement assay
US7691647B2 (en) 2005-01-21 2010-04-06 Siemens Healthcare Diagnostics Inc. Compositions for use as a signal generation component and methods of using same
WO2017127684A1 (en) 2016-01-21 2017-07-27 SeLux Diagnostics, Inc. Methods for rapid antimicrobial susceptibility testing
US9834808B2 (en) 2016-01-21 2017-12-05 SeLux Diagnostics, Inc. Methods for rapid antibiotic susceptibility testing
EP3845663A1 (en) 2016-01-21 2021-07-07 Selux Diagnostics Inc. Methods for rapid antimicrobial susceptibility testing
WO2018119439A1 (en) 2016-12-23 2018-06-28 SeLux Diagnostics, Inc. Methods for improved rapid antimicrobial susceptibility testing
US11845976B2 (en) 2019-08-27 2023-12-19 SeLux Diagnostics, Inc. Systems and methods for performing antimicrobial susceptibility testing

Also Published As

Publication number Publication date
ATE21173T1 (en) 1986-08-15
SE425439B (en) 1982-09-27
EP0064484A3 (en) 1983-01-19
JPH049263B2 (en) 1992-02-19
DE3272260D1 (en) 1986-09-04
EP0159066A1 (en) 1985-10-23
EP0064484B1 (en) 1986-07-30
US4565790A (en) 1986-01-21
JPS57186170A (en) 1982-11-16

Similar Documents

Publication Publication Date Title
EP0064484B1 (en) Method for fluorescence spectroscopic determination of a biologically active substance
US4374120A (en) Fluorescence spectroscopy assay means with fluorescent chelate of a lanthanide
EP0735360B1 (en) Determination of the number of phycoerythrin molecules on calibration beads for flow cytometry
EP0154734B1 (en) Immediate ligand detection assay, a test kit and its formation
EP0175545B1 (en) Measuring intensity fluctuations and determining an analyte thereby
US4148869A (en) Immunological reagent and method of using same
SE454115B (en) HOMOGENIC PHASE ANALYSIS WITH LANTANIDE KELAT AS BRAND SUBSTANCE
JPS59195160A (en) Fluorescent multi-parameter dispersoid analysis
DK158284D0 (en) MONOCLONAL ANTIBODIES DERIVED FROM CROSS-BONDED FIBRIN DERIVATIVES AND ANALYSIS METHOD FOR DETERMINING THESE DERIVATIVES
ES2077726T3 (en) TEST KIT FOR THE DETERMINATION OF AN ANALYTE IN A PASTO SAMPLE, ESPECIALLY IN THE FECES.
CA2149903A1 (en) Use of capillary electrophoresis for quantitating the concentration of protein components and of the total protein in fluids
CN101666801A (en) Hepatitis B virus surface antigen detection particles, preparation thereof and use thereof
JPH0219428B2 (en)
Bunting et al. Energy transfer distance measurements in immunoglobulins: II. Localization of the hapten binding sites and the interheavy chain disulfide bond in rabbit antibody
Nargessi et al. Solid-phase fluoroimmunoassay of human albumin in biological fluids
Thiel et al. Quantitative immunoautoradiography at the cellular level. I. Design of a microphotometric method to quantitate membrane antigens on single cells using 125I-labeled antibodies
EP0132556B1 (en) Immunoassay
CN101769928B (en) Core antibody testing fine particles for hepatitis B virus, and preparation and application thereof
Yeatman et al. Rapid analysis of carcinoembryonic antigen levels in gallbladder bile. Identification of patients at high risk of colorectal liver metastasis.
US7211441B2 (en) Lipoprotein assay
Goldberg et al. Quantitation of collagen in polyacrylamide gels by fluorescent scanning of MDPF1-labeled proteins: An improvement over densitometric scanning of gels stained by coomassie blue
Braun et al. Luminometric assays of seven acute-phase proteins in minimal volumes of serum, plasma, sputum, and bronchioalveolar lavage.
Brighton Assay of materials used in immunofluorescence techniques
US5187106A (en) Method and apparatus for homogeneous fluorescence measurements
Blom et al. A turbidimetric continuous-flow system for immunochemical quantitation of blood proteins by use of a modified photometer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT NL

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI NL

17P Request for examination filed

Effective date: 19830610

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI NL

REF Corresponds to:

Ref document number: 21173

Country of ref document: AT

Date of ref document: 19860815

Kind code of ref document: T

ITF It: translation for a ep patent filed

Owner name: BARZANO' E ZANARDO ROMA S.P.A.

REF Corresponds to:

Ref document number: 3272260

Country of ref document: DE

Date of ref document: 19860904

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20010330

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20010404

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20010409

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20010411

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20010412

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20010430

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20010621

Year of fee payment: 20

BE20 Be: patent expired

Free format text: 20020408 *WALLAC OY

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020407

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020407

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020407

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020408

Ref country code: AT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020408

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Effective date: 20020407

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20020408

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20020408